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Independent effect of prior exacerbation frequency and disease
severity on the risk of future exacerbations of COPD: a
retrospective cohort study
Miguel Santibañez Margüello1,9, Roberto Garrastazu2, Mario Ruiz-Nuñez3, Jose Manuel Helguera4, Sandra Arenal5,
Cristina Bonnardeux6, Carlos León5, Marc Miravitlles7 and Juan Luis García-Rivero8,9
Few studies have researched the independent effect of COPD severity on the risk of future exacerbations adjusted by previous
exacerbation frequency. We aimed to analyse the independent effect of COPD severity on the risk of exacerbations in the following
year, and whether this effect was stronger or not than the effect of a previous history of exacerbations. We conducted a
retrospective population-based cohort study including 900 patients with confirmed COPD. Exacerbation frequency was observed
for the previous year and for the following year. Patients were defined as ‘Frequent Exacerbator’ (FE) phenotype if they suffered ⩾ 2
exacerbations in a year, and were categorised according to the severity of COPD (GOLD Grades 1–4). Odds ratios (ORs) were
estimated by logistic regression adjusting for age, gender, smoking status, severity of COPD and being FE in the previous year. The
main predictor of being FE among all grades of COPD severity was a history of frequent exacerbations in the previous year: adjusted
OR 4.97; 95% confidence interval (CI) (3.54–6.97). COPD severity was associated with a higher risk of being FE: Crude OR GOLD
Grade 4 3.86; 95% CI (1.50–9.93). However, this association diminished after adjusting for being FE in the previous year: adjusted OR
2.08; 95% CI (0.75–5.82). Our results support that a history of frequent exacerbations in the previous year is the most important
independent predictor of exacerbations in the following year, also among the most severe COPD patients. Severity of COPD would
be associated with a higher risk of exacerbations, but this effect would be partly determined by the exacerbations suffered in the
previous year.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is one of the most
common lung conditions observed in clinical practice and the
third leading cause of death in the world.1 The association of
COPD and smoking is well established. However, an increasing
number of studies have reported a significant prevalence of COPD
among non-smokers.2–4
Exacerbations of COPD are episodes of worsening of symptoms
that carry significant consequences for patients,5–7 being respon-
sible for a large proportion of the health-care costs attributable to
this prevalent condition.8 Consequently, their prevention is a key
component of COPD-management strategies.9,10
Despite the importance of exacerbations, we know relatively
little about their determinants, probably because the hetero-
geneity of COPD exacerbations reflects their dependence on a
complex spectrum of multiple risk factors.5
The most consistent predictor of exacerbations appears to be a
previous history of exacerbations.11 This would be supported by
new large observational cohort studies such as ‘The Evaluation of
COPD Longitudinally to Identify Predictive Surrogate Endpoints
(ECLIPSE) Study’,12 potentially indicating a definable phenotype of
exacerbation susceptibility. However, this observational study did
not include milder forms of COPD (Mild-GOLD grade 1), nor did it
include COPD-confirmed patients without a history of tobacco
consumption.
Although exacerbations are generally considered to become
more frequent as the severity of the underlying COPD increases,13
very few studies have researched the independent effect of COPD
severity adjusted by a previous history of exacerbations.
We used the data from a retrospective population-based cohort
study, including Mild-GOLD grade 1 or Non-smoker patients with
confirmed COPD, to test whether a history of frequent exacerba-
tions is the most important predictor of exacerbations in the
following year, with independence of disease severity. In addition,
we tried to analyse the independent effect of disease severity on
the risk of susceptibility to exacerbations.
RESULTS
Among 900 patients with confirmed COPD, 194 (21.6%) were
women. The overall mean age was 71.2 years (s.d. 11.0), with a
mean of years since COPD diagnosis of 6.6 years (s.d. 5.5). In all,
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15.7% of the COPD-confirmed patients were never-smokers. The
baseline characteristics of the patients are reported in Table 1.
With regard to COPD severity, most of the patients were
moderate-GOLD grade 2 (60%); 26.2% were severe-GOLD grade 3;
10.4% were mild-grade 1; and 3.5% were very severe-GOLD grade
4. Twenty eight per cent of the mild-GOLD grade 1 patients
developed two or more exacerbations in the following year
(‘FE’ phenotype). Incidence of ‘FE’ phenotype increased in our
study with increasing disease severity (40%, 42% and 60% among
GOLD grades 2, 3 and 4 were ‘FE’ phenotype, respectively).
In all, 85% of our sample was affected by at least one of the
studied co-morbidities. The most prevalent co-morbidity was high
blood pressure, affecting 60.2% of patients. See Supplementary
Table 2.
Table 2 shows the associations between a history of exacerba-
tions and the risk of suffering frequent exacerbations in the
following year. Each exacerbation during the past 4 years (range
0–36) increased the risk of being ‘FE’ the next year by 1.20. Each
exacerbation during the previous year (range 0–10) increased the
risk of being ‘FE’ phenotype the next year by 1.76. As during
4 years the number of exacerbations was approximately four times
as high as the number of exacerbations in a single year, this odds
ratio (OR) of 1.20 would be equivalent to an average OR per year
of 2.07 (2.07 = 1.204).
A statistically significant dose–response p trend was obtained
after ordinal-categorising the number of exacerbations during
2011 (adjusted linear P trend o0.001) into 0, 1 and⩾ 2
exacerbations. When categorising into ‘FE’ versus ‘Infrequent
Table 1. Baseline sociodemographic, lifestyle and clinical characteristics of the patients
IE FE Total P value
N= 568 Row % N=332 Row % N= 900 Column %
Age, mean [s.d.] 69.8 [11.4] 73.6 [9.8] 71.2 [11.0] o0.001
Gender
Female 123 63.4 71 36.6 194 21.6 0.924
Male 445 63.0 261 37.0 706 78.4
Year since COPD diagnosis, mean [s.d.] 6.2 [5.1] 7.4 [6.1] 6.6 [5.5] 0.001
Smoking
Never-smoker 84 62.2 51 37.8 135 15.7 0.001
Former smokers 289 57.9 210 42.1 499 57.9
Current smokers 166 72.8 62 27.2 228 26.5
Missing values 29 76.3 9 23.7 38 4.2
BMI, mean [s.d.] 28.8 [4.7] 28.9 [5.3] 28.9 [4.9] 0.89
Normal weight (18.5–24.9) 91 59.9 61 40.1 152 18.8 0.396
Overweight (25–29.9) 198 63.9 112 36.1 310 38.4
Obesity (⩾30) 213 63.4 123 36.6 336 41.6
Underweight (o18.5) 4 40 6 60 10 1.2
Missing values 62 67.4 30 32.6 92 10.2
BODE-BMIa
BMI 421 491 62.9 290 37.1 781 96.7 0.44
BMI ⩽ 21 15 55.6 12 44.4 27 3.3
Missing values 62 67.4 30 32.6 92 10.2
GOLD Grades (FEV1)
Grade 1 (⩾80%) 54 72 21 28 75 10.4 0.029
Grade 2 (⩾50–80%) 259 59.8 174 40.2 433 59.9
Grade 3 (⩾30–49.9%) 110 57.9 80 42.1 190 26.3
Grade 4 (o30%) 10 40 15 60 25 3.5
Missing values 135 42 177
History of exacerbations
Number of exacerbations in the previous year, mean [s.d.] 0.92 [1.20] 2.39 [2.01] 1.46 [1.71] o0.001
Number of exacerbations in the previous 4 years, mean [s.d.] 3.1 [3.56] 7.49 [6.32] 4.72 [5.21] o0.001
Number of exacerbations in the previous year
None (0 exacerbations) 275 84.6 50 15.4 325 36.1 o0.001
1 exacerbation 163 68.3 75 31.7 238 26.5
⩾ 2 exacerbations 130 38.6 207 61.4 337 37.4
History of severe exacerbations (hospitalised for exacerbation) in the previous year
Number of COPD admissions, mean [s.d.] 0.17 [0.51] 0.51 [1.03] 0.29 [0.76] o0.001
None (0 COPD admissions) 497 68.1 233 31.9 730 81.1 o0.001
1 COPD admission 54 47 61 53 115 12.8
⩾ 2 COPD admissions 17 30.9 38 69.1 55 6.1
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FE, frequent exacerbations in the following year; FEV1, forced expiratory
volume in 1 s; IE, infrequent exacerbations in the following year.
aRisk cutoff point for BMI according to BODE index.
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Exacerbations’ (IE) phenotype during the previous year, an
adjusted Odds Ratio (ORa) of 4.97, 95% CI (3.54–6.97), was
obtained with independence of COPD severity.
With respect to the stability of the frequent-exacerbation
phenotype over time, among the 563 patients with infrequent
exacerbations in the previous year, 438 also had infrequent
exacerbations in the following year (negative predictive value,
77.8%). Among the 337 patients with frequent exacerbations in
the previous year, there were 207 who had frequent exacerbations
in the following year (positive predictive value, 61.4%); 85.5% of
patients with frequent exacerbations in the previous year had at
least one exacerbation in the following year. Thus, exacerbation
frequency in the previous year had a sensitivity of 51.9% and a
specificity of 85.8% for the frequency in the following year (see
Table 3).
In addition, in Table 3 absolute risk reduction—also called risk
difference—is presented. The risk difference was 38% (85.46 per
cent—47.42 per cent = 38 per cent). This means that if 100
Table 2. Crude and adjusted ORs according to previous exacerbations for the risk of suffering frequent exacerbations in the following year
IE FE ORc 95% CI ORa 95% CI
N= 568 N= 332
History of exacerbations
Number of exacerbations in the previous year (continuous) — — 1.85 1.66–2.06 1.76 1.56–2.00
Number of exacerbations in the previous four years (continuous) — — 1.24 1.19–1.30 1.20 1.15–1.26
Frequent exacerbations in the previous year
Infrequent exacerbations (⩽1) 438 125 1 — 1 —
Frequent exacerbations (⩾2) 130 207 5.58 4.15–7.50 4.97 3.54–6.97
Number of exacerbations in the previous year
None (0 exacerbations) 275 50 1 — 1 —
1 exacerbation 163 75 2.53 1.69–3.80 1.86 1.18–2.95
⩾ 2 exacerbations 130 207 8.76 6.03–12.71 6.77 4.45–10.28
Linear P trend o0.001 o0.001
History of severe exacerbations (hospitalised for exacerbation) in the previous year
Number of COPD admissions (continuous) — — 1.91 1.53–2.38 1.13 0.93–1.37
Frequent severe exacerbations in the previous year
None (0 COPD admissions) 497 233 1 — 1 —
⩾ 1 COPD admissions 71 99 2.97 2.11–4.19 2.13 1.45–3.14
Number of severe exacerbations in the previous year
None (0 COPD admissions) 497 233 1 — 1 —
1 COPD admission 54 61 2.41 1.62–3.59 1.75 1.12–2.72
⩾ 2 COPD admissions 17 38 4.77 2.64–8.63 3.35 1.75–6.41
Linear P trend o0.001 o0.001
Abbreviation: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FE, frequent exacerbations in the following year; IE, infrequent
exacerbations in the following year; OR, odds ratio; ORc, crude OR; ORa, adjusted OR by age, gender, smoking status and COPD severity (GOLD grades 1–4).
Table 3. Stability of the frequent-exacerbation phenotype over time
Number of exacerbations in the following year
0 ⩾ 1 Total Risk (%) RDb 95% CI Se (%) Sp (%) PV+ (%) PV− (%)
N=345 N=555 N= 900
Frequent exacerbations in the previous year
Infrequent exacerbations ⩽ 1) 296 267 563 47.42
Frequent exacerbations (⩾2) 49 288 337 85.46 38.04 32.45–43.62 51.89 85.8 85.46 52.58
⩽ 1 (IE) ⩾ 2 (FE) Total Risk (%) RD 95% CI Se (%) Sp (%) PV+ (%) PV- (%)
N=568 N=332 N= 900
Frequent exacerbations in the previous year
Infrequent exacerbations (⩽1) 438 125 563 22.2
Frequent exacerbations (⩾2) 130 207 337 61.42 39.22 32.99–45.45 62.35 77.11 61.42 77.8
Abbreviations: CI, confidence interval; FE, frequent exacerbations in the following year; IE, infrequent exacerbations in the following year; PV(+), positive
predictive values; PV(− ), negative predictive values; RD, risk difference with its 95% CI; Se, sensitivity; Sp, specificity.
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patients were converted from FEs to infrequent exacerbators, 38%
would be prevented from developing an exacerbation in the
following year.
COPD severity according to forced expiratory volume in 1 s
(FEV1) was associated with a higher risk of being ‘FE’ phenotype in
the following year in our crude models: crude OR GOLD grade 4,
3.86; 95% CI (1.50–9.93) (see Table 4). After adjusting for age,
gender and smoking status, results remained significant.
However, when adding ‘Frequent of exacerbations in the
previous year’ to the multivariable model, adjusted p trend
did not yield statistical significance because GOLD grade 3
patients (ORa2 1.38) were not at a higher risk of being ‘FE’
phenotype than GOLD grade 2 patients (ORa2 1.41). Even the
crude association for the very severe-GOLD grade 4 patients
diminished and did not yield statistical significance: ORa2 2.08;
95% CI (0.75–5.82).
With respect to the remaining sociodemographic (age and
gender), lifestyle (tobacco and BMI) and clinical variables
(co-morbidities), only age was statistically significantly associated
with a higher risk of being ‘FE’ phenotype in the previous year in
the multivariable models (see Table 5). None of the studied
co-morbidities was an independent predictor of ‘FE’ phenotype.
See Supplementary Table 3.
DISCUSSION
Main findings
The most important independent predictor of ‘Frequent Exacer-
bations’ in the following year was the exacerbation frequency
during the previous year, with statistically significant dose–
response patterns. This effect was independent of COPD severity
and main confounders identified in our study. The number of
Table 4. Crude and adjusted odds ratios according to COPD severity for the risk of suffering frequent exacerbations in the following year
COPD severity according to FEV1 IE FE ORc 95% CI ORa1 95% CI ORa2 95% CI
N=568 N=332
FEV1—per 5% decrease in % of predicted value — — 1.08 1.03–1.13 1.12 1.07–1.16 1.04 0.99–1.10
FEV1—mild-GOLD grade 1 (reference category) 54 21 1 — 1 — 1 —
FEV1—moderate-GOLD grade 2 259 174 1.73 1.01–2.96 1.64 0.93–2.88 1.41 0.77–2.56
FEV1—severe-GOLD grade 3 110 80 1.87 1.05–3.34 1.84 1.00–3.38 1.38 0.72–2.64
FEV1—very severe-GOLD grade 4 10 15 3.86 1.50–9.93 3.60 1.37–9.44 2.08 0.75–5.82
Linear P trend 0.01 o0.001 0.286
Missing values 135 42 0.80 0.43–1.47 0.82 0.43–1.57 0.82 0.40–1.67
Abbreviations: CI, confidence interval; FE, frequent exacerbations in the following year; FEV1, forced expiratory volume in 1 s; IE, infrequent exacerbations in
the following year; OR, odds ratio; ORc, crude OR; ORa1, adjusted OR by age, gender and smoking status; ORa2, adjusted OR adding to the multivariable
model: FE phenotype (yes/no) in the previous year.
Table 5. Crude and adjusted ORs according to sociodemographic characteristics, for the risk of suffering frequent exacerbations in the following
year
IE FE ORc 95% CI ORa 95% CI
N= 568 N=332
Age—per 10-year increase — — 1.35 1.19–1.53 1.27 1.07–1.5
Gender
Female 123 71 1 — 1 —
Male 445 261 1.02 0.73–1.41 1.07 0.68–1.68
Smoking
Never-smoker 84 51 1 — 1 —
Former smokers 289 210 1.2 0.81–1.77 1.11 0.66–1.89
Current smokers 166 62 0.62 0.39–0.97 0.76 0.42–1.39
Linear P trend 0.009 0.228
BMI
Normal weight (18.5–24.9) 91 61 1 — 1 —
Overweight (25–29.9) 198 112 0.84 0.57–1.26 0.85 0.51–1.41
Obesity (⩾30) 213 123 0.86 0.58–1.28 0.82 0.5–1.34
Underweight (o18.5) 4 6 2.24 0.61–8.26 0.83 0.19–3.58
Linear P trend 0.831 0.463
BODE-BMIa
BMI 421 484 285 1 — 1 —
BMI ⩽ 21 22 17 1.31 0.68–2.51 1.47 0.66–3.26
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obsrtuctive pilmonary disease; FE, frequent exacerbations in the following year; IE,
infrequent exacerbations in the following year; OR, odds ratio; ORa, adjusted OR by age, gender, smoking status, COPD severity (GOLD grades 1–4) and FE
phenotype (yes/no) in the previous year; ORc, crude OR.
aRisk cutoff point for BMI according to BODE index.
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exacerbations during the past 4 years (2008–2011) would also be a
good independent predictor of ‘FE’ phenotype.
With regard to COPD severity, incidence of ‘FE’ phenotype’
increased in our study with increasing disease severity, and thus
COPD severity was associated with ‘FE’ phenotype in the following
year in our crude models. However, after adding ‘Frequency of
exacerbations in the previous year’ as a confounding variable, the
importance of disease severity as an independent predictor
diminished. This strongly suggests that the number of
exacerbations in the previous year is associated simultaneously
with the COPD severity and the number of exacerbations in the
following year. Thus, a history of exacerbations would be the most
important predictor of ‘FE’ phenotype among all grades of disease
severity, and even for the most advanced severity grades (very
severe-GOLD grade 4) the exacerbations suffered in the past
would act as an important intermediate step in the causal
pathway of being ‘FE’ phenotype.
Interpretation of findings in relation to previously published work
The importance of prior exacerbation frequency on the risk of
future exacerbations is supported by the largest prospective
cohort study (ECLIPSE Study)12 and numerous additional observa-
tional studies,14–17 as well as previous large intervention
studies.18–20
With regard to COPD severity, some published studies support
this rationale to some extent,6,12,17,21 but further studies with a
higher sample size must focus on the real independent effect of
COPD severity on the risk of exacerbation frequency.
In our sample, 10.4% of included patients were GOLD stage 1. In
all, 28% of these mild-GOLD stage 1 patients developed two or
more exacerbations in the following year (‘FE’ phenotype). These
results provide clinical original information with respect to
previous studies,12,15 supporting the hypothesis that there may
therefore be a phenotype of exacerbation susceptibility that
includes milder forms of COPD.
Strengths and limitations of this study
One limitation is the retrospective study design based on
secondary information available in clinical databases that were
not specifically designed with this project in mind. In retrospective
studies based on secondary information (records), a main
limitation could be the low quality of that information; this could
be either because of insufficient completion of medical records or
lack of agreement among different records. To minimise any bias,
we a priori decided to use only variables in which the data
appeared systematically and objectively collected and in which
the data appeared internally consistent. Where possible, we
obtained agreement by making a comparison between the
primary care and hospital records. In addition, it is important to
indicate that all included records were checked for valid
spirometric results confirming COPD diagnosis.
In some important variables such as FEV1, a non-negligible
percentage of missing values was obtained (N= 177, 19.7%)
because the numeric specific value was not registered even
though an obstructive spirometry was retrieved from the
databases. We performed a sensitivity analysis concerning the
effect of missing FEV1 data. We did so by treating missing values
as a separate category and comparing the association between
the missing values and the risk of suffering frequent exacerbations
in the following year. The missing values showed greater similarity
to the reference category (mild-GOLD grade 1) than to the more
severe-GOLD grades 2–4. If those missing values were not actually
unknown but were mild-GOLD grade 1, similar OR for the
remaining GOLD grades 2–4 would have been obtained with a
more precise 95% CI. This suggested that the missing data did not
unduly bias our findings.
External validity is one of the main limitations regarding clinical
trials.22,23 This problem can also affect observational studies based
on strict inclusion and exclusion criteria.24 We checked that our
final analysed sample was representative with respect to age,
gender and primary health-care centre with respect to the base
population. A major strength of our study is that our sample
reflected a population-based (real-life) sample, and therefore mild
stages and non-smokers with confirmed COPD were identified
and included in the random sample. Our prevalence of 15.7% of
Population affiliated to
public health system in
Cantabria 35 years
N=362.372  
Population identified
with diagnosis of
COPD in OMI-AP
(R91 and R95)
N=9.334  
Simple random
sample N=2.000
Review of clinical
records and hospital
reports
Population absent or
not available in
Cantabrian health
records N=11
COPD ruled out
(excluded)
N=197  
COPD CONFIRMED
(included)
N=900  
COPD unconfirmed
(excluded and included
in a sensitivity analysis)
N=892  
OMI-AP search
Figure 1. Flow chart for selection of the study sample.
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confirmed COPD in never-smokers is also supported by published
studies.2–4
The fact that information was based on records makes the
existence of bias arising from the lack of blindness among
patient's care providers (who treated patients retrospectively
blinded to the development of the study) improbable. To
minimise a selection bias, only COPD-confirmed cases were
chosen, and an attempt to obtain the independent effect of
predictors was made in the epidemiological and statistical
approach by controlling confounding and stratified analysis.
Implications for future research, policy and practice
Some patients with milder disease (GOLD stages 1) are also
subject to frequent exacerbations, suggesting a distinct suscept-
ibility phenotype. This highlights the necessity of reconsidering a
more in-depth monitoring and therapeutic and preventive
strategies in patients at GOLD grade 1 level classified as ‘FE’
phenotype.
Conclusions
Our study supports the hypothesis that the most important
independent predictor of ‘FE’ phenotype in the following year is a
history of frequent exacerbations in the previous year, among all
grades of COPD severity. Severity of COPD would be associated to
a less extent with a higher risk of being ‘FE’ phenotype, and this
effect would be in part determined by the exacerbations suffered
in the previous year.
MATERIALS AND METHODS
Design and participants
This is a retrospective population-based cohort study. Methods have been
described elsewhere.25 All the patients⩾ 35 years old, with prevalent codes
‘R91’ or ‘R95’ according to the lnternational Classification of Primary Care
(ICP),26 were identified through electronic clinical databases in the
province of Cantabria (Northern Spain) on 31 December 2011. The
recruitment criteria included no restriction according to a history of
tobacco consumption or degree of FEV1 impairment. A total of 9,334
potential COPD patients were identified out of the total population of
362,372 people registered in Cantabria.
A sample of 2,000 patients was obtained by simple random sampling. A
comparison of the 2000 sampled patients with respect to the 9,334
potential COPD patients, on basic sociodemographics, is presented in
Supplementary Table 1. Spirometric data were carefully revised for each of
these patients. COPD diagnosis was considered as confirmed if a
spirometry with bronchodilatation test consistent with obstructive disease
(defined as a FEV1/forced vital capacity ratio of o0.7) was retrieved from
the databases, and it was rejected if spirometry was not consistent with
obstructive disease. Diagnosis of COPD was confirmed in 900 patients
(45.3%), rejected in 197 patients (9.9%) and not confirmed—not rejected in
the remaining patients (44.8%). Final analysis was restricted to COPD-
confirmed patients. The flow chart for selecting study patients is shown in
Figure 1.
Data sources and variables
Data for each patient were individually gathered from primary care
medical electronic medical records (OMI-AP)27–29 and complemented with
hospital electronic records (eVISOR), which contain information about
urgent assistance, consultations done by lung specialists and hospital
admissions.
Clinical and demographic characteristics of all patients were recorded,
including age, years since diagnosis of COPD, treatments and vaccinations,
smoking status, alcohol consumption and co-morbidities.
Records of diagnoses of selected co-morbidities,30,31 including diabetes,
osteoporosis, atrial fibrillation, ischaemic heart disease, heart failure and
high blood pressure, occurring before the start of the study, were retrieved
from the database.
Exacerbations were defined as events that led a care provider to
prescribe antibiotics or corticosteroids (or both; moderate exacerbations)
or that led to hospitalisation (severe exacerbations). This case definition
therefore met the criteria for a definition of health-care utilisation.12,32,33
Exacerbation frequency was observed for the previous year (2011), the
previous four years (2008–2011) and for the following year (2012). We also
defined frequent exacerbations (‘FE’ phenotype) as two or more
exacerbations in a year, because this definition coincides with current
health-care utilisation criteria for frequent exacerbations.12,32
Statistical analyses
Discrete variables were expressed as counts (percentage) and continuous
variables as mean (s.d.). Statistical differences between groups were
assessed with the χ2-test or Fisher’s exact test, when appropriate, for
categorical variables. The Student’s t-test was used for the continuous
variables.
Exacerbation frequency (both moderate and severe exacerbations) for
the following year (2012) was treated as a dichotomous dependent
variable in the regression models: ‘FE’ phenotype versus ‘Infrequent
Exacerbator’ (IE) phenotype (none or one exacerbation).
Exacerbation frequencies ‘during the previous year (2011)’ and ‘during
the last four years (2008–2011)’ were treated as independent variables and
included as continuous variables in the regression models.
Exacerbation frequency ‘during the previous year (2011)’ was also
ordinal-categorised as ‘0 exacerbations’, ‘1 exacerbation’ and ‘⩾ 2
exacerbations’. Next, the ‘0’ and ‘1’ categories were combined, and thus
a dichotomous variable ‘FE’ versus ‘IE’ phenotype in the previous year was
obtained.
Patients were also ordinal-categorised into 4 categories of severity of
COPD according to FEV1 quantitative results, as defined by the Global
Initiative for Chronic Obstructive Lung Disease (GOLD grades 1–4).34 Last,
FEV1 was transformed in an ordinal scale according to per 5% decrease in
per cent of predicted value.12
Crude and adjusted ORs with their 95% CI were estimated by
unconditional logistic regression, adjusting for age (continuous), gender,
smoking status (no smoker, former smoker, current smoker), severity of
COPD (ordinal GOLD grades 1–4) and ‘FE’ phenotype (yes/no) in the
previous year.
Tests for OR trends were calculated for the ordinal independent
variables using logistic models that included categorical terms as
continuous variables. For these trend tests, we used the likelihood
ratio test.
The final sample size (n=900) would have sufficient power (1− β490%)
to detect relative risks ⩾ 1.16 as significant for a 50% risk of the effect in
the unexposed, considering an unexposed/exposed ratio of 1, using a two-
tailed χ2-test with an α level o0.05.
To assess the stability of the frequent-exacerbation phenotype over
time, we calculate positive and negative predictive values, sensitivity and
specificity. As impact measure, the absolute risk reduction, also called risk
difference, was estimated.
The α error was set at 0.05, and all P values were bilateral. All statistical
analyses were conducted using IBM SPSS Statistics version 22.0.
Approval of the research protocol was obtained from the Clinical
Research Ethics Committee of Cantabria before the acquisition of data.
Patient records/information was anonymised and de-identified before
analysis.
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